Last reviewed · How we verify
Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Menest | Estrogens, Esterified | Pfizer Inc. | Estrogen | Estrogen receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 1 drug in Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease:
- Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease treatment updates — RSS
- Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease treatment updates — Atom
- Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease treatment updates — JSON
Cite this brief
Drug Landscape (2026). Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/breast-cancer-for-palliation-only-in-appropriately-selected-women-and-men-with-metastatic-disease. Accessed 2026-06-10.
Related
- Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing